Eplontersen · Wainua
RNA / oligonucleotide
Evidence outlook
Approved: Transthyretin Amyloidosis with Polyneuropathy
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Weak signal
Also in development:Transthyretin Amyloidosis with Cardiomyopathy · Phase 3 · investigational in the US
Also approved (1)
- Treatment of hereditary transthyretin-mediated amyloidosis (ATTRv) in adult patients with stage 1 or stage 2 polyneuropathy.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT04136184 NCT04136184 · Transthyretin Amyloidosis with Polyneuropathy This open-label Phase 3 trial randomized 168 people with hereditary transthyretin amyloid polyneuropathy 6:1 to eplontersen or inotersen, but the primary efficacy comparisons were made between the eplontersen group and an external placebo group from an earlier, separate trial (NEURO-TTR). At Week 66 eplontersen was favored on neuropathy impairment (mNIS+7, LS mean difference -24.76, 95% CI -30.96 to -18.56) and on Norfolk quality of life (-19.74, 95% CI -25.63 to -13.84), and serum TTR fell by 70.42 percentage points more at Week 65, all with p<0.0001. Because the comparison group was neither randomized nor treated within this study, and no one was blinded, these results are more open to bias than a concurrent placebo-controlled comparison. Registry: NCT04136184 | 3 | Change From Baseline in Modified Neuropathy Impairment Score Plus 7 (mNIS+7) at Week 66 (Baseline, Week 66); Change From Baseline in the Norfolk Quality of Life Diabetic Neuropathy (QoL-DN) Questionnaire at Week 66 (Baseline, Week 66); Percent Change From Baseline in Serum TTR Concentration at Week 65 (Baseline, Week 65); Percent Change From Baseline in Serum TTR Concentration at Week 35 (Baseline, Week 35); Change From Baseline in Modified Neuropathy Impairment Score Plus 7 (mNIS+7) at Week 35 (Baseline, Week 35) 2023-04-11 | Completed. Key figures are not recorded here; the rationale explains the result. | Weak signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.
Phase 3 (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (1)
What this study did
Phase 1 (2)
What this study did
What this study did
Appears in other studies (1)
Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.
Phase 2 (1)
What this study did
Competitive landscape
Other Transthyretin (TTR) drugs
Acoramidis, Patisiran, Vutrisiran, Inotersen, Cliramitug and 3 more. Compare all 9 Transthyretin (TTR) drugs
This mechanism is crowded: 8 other tracked programmes target it, none of them ahead of this one.
This drug's own stage for Transthyretin Amyloidosis with Polyneuropathy: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Eplontersen (Wainua): this drug | Approved | RNA / oligonucleotide | Transthyretin (TTR) | Weak signal | No reviewed efficacy summary in this indication | |
| Patisiran (ONPATTRO) | Approved | RNA / oligonucleotide | Transthyretin (TTR) | Reliable signal | NCT01960348: Modified Neuropathy Impairment Score +7 (mNIS+7) (18mo): Patisiran (ALN-TTR02) -6.03 score on a scale (Standard Error 1.739) | Placebo 27.96 score on a scale (Standard Error 2.602) | |
| Vutrisiran (AMVUTTRA) | Approved | RNA / oligonucleotide | Transthyretin (TTR) | Partial signal | NCT03759379: Change From Baseline in the Modified Neurologic Impairment Score +7 (mNIS+7) at Month 9 Between the Vutrisiran Group (HELIOS-A) and the External Placebo Comparator Group [APOLLO (NCT01960348)] (Baseline, Month 9): External Placebo Comparator (APOLLO) 14.76 score on a scale (Standard Error 2) | Vutrisiran + Vutrisiran (HELIOS-A) -2.24 score on a scale (Standard Error 1.43) | |
| Inotersen (Tegsedi) | US approval withdrawn | RNA / oligonucleotide | Transthyretin (TTR) | Reliable signal | No reviewed efficacy summary in this indication | |
| Coramitug | Phase 3(overall) | Monoclonal antibody | Transthyretin (TTR) | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Nucresiran | Phase 3 | RNA / oligonucleotide | Transthyretin (TTR) | not yet graded | No reviewed efficacy summary in this indication |
Compare side by side
1 further pair is tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Wainua (Eplontersen) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2029 (2)
August 2029 (2)
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent